|Bid||0.00 x 100|
|Ask||0.00 x 800|
|Day's Range||312.98 - 322.78|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||20.50|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||389.35|
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
The long-term growth strategy of Samsung was thrown into doubt on Wednesday after regulators in South Korea suspended trading of a key biopharmaceutical affiliate that the conglomerate hoped would power ...
More and more rare-disease medications have been approved in recent years, but a tangle of complications can keep promising but expensive therapies out of reach for patients.
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.
Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.
Namely, a strong dollar hurting export demand, tariffs, higher oil, transportation, labor and interest costs, which all can negatively impact profit margins. Rising mortgage rates, loss of deductions in high-tax states and overheated markets are hampering high-end housing. With US oil companies solidly profitable at $50 a barrel, fundamentals support lower fuel inputs as commodities will tend to trade close to the cost of production over time.
The company will next report results on Feb. 1 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $10.99 billion. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues.
Biogen Inc. (NASDAQ: BIIB) fell alongside the broad market selloff in October, but Biogen stock rallied rebounded when it reported third-quarter results. With BIIB stock price still in value territory at 15 times earnings and 11 times forward earnings, investors should take a closer look at the latest results.
"We've seen discounting at ranges from as low as 10 percent to as high as around 80 percent," Chief Executive Officer Richard Gonzalez said on a conference call with analysts. The highest discounting was seen in Nordic countries, Gonzalez said, adding that the company believes discounting would likely "moderate" going forward. "We do not have evidence from prior European Union biosimilar launch dynamics that the pace of discounting will slow in the second year of availability," Leerink analyst Geoffrey Porges said.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he likes Biogen Inc's (NASDAQ: BIIB ) management, but he doesn't like the hype around the new Alzheimer drug. People don't want to own ...
Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. Alexander John Denner, also known as Alex PhD. Before launching his own investment fund, Mr. Denner sharpened his investment skills as a portfolio manager at Viking Global, and as a Senior Managing Director at Icahn Capital […]
Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.
There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.
Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.
Biogen and Japanese partner Eisai may be at odds in developing a treatment for Alzheimer's disease, an analyst said Monday after a paradoxical presentation last week.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Clearbridge Investments published its third quarter commentary. The prevailing theme of the commentary is that we are on the cusp of a shift from growth and momentum outperformance to value investing. The winner of the current cycle, S&P 500 stocks, will perform poorly in the coming cycle and value stocks will outperform. Clearbridge mentions American […]
An experimental drug from drugmakers Biogen and Eisai emerged this summer with the potential to do what no other medication has been able to: slow the development of Alzheimer’s disease, a progressive and devastating disease marked by cognitive decline. With new study results, presented by the two companies early Thursday at a European conference, the uncertainty lingers on, even as it has become more complicated. Biogen shares (BIIB) dropped more than 3% in heavy Thursday trade before evening out to a 1.2% decline, while Eisai shares dropped 5.7% (JP:4523) Biogen shares also declined the day before the BAN2401 results, and dropped 1.8% in Friday premarket trade.